Why CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts

Simply Wall St.16:26

CSL has recently cut its FY26 revenue and profit forecasts following earnings downgrades, writedowns and impairments tied to shifts in US immunoglobulin sales channels and softer China albumin prices,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643214189?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2026-06-13 16:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643214189","market":"hk","top_or_hot":-1,"title":"Why CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts","media":"Simply Wall St.","content":"<div>\n<p>CSL has recently cut its FY26 revenue and profit forecasts following earnings downgrades, writedowns and impairments tied to shifts in US immunoglobulin sales channels and softer China albumin prices,...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-13 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CSL has recently cut its FY26 revenue and profit forecasts following earnings downgrades, writedowns and impairments tied to shifts in US immunoglobulin sales channels and softer China albumin prices,...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai","article_id":"2643214189","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643214189","pubTimestamp":1781339195,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CSL has recently cut its FY26 revenue and profit forecasts following earnings downgrades, writedowns and impairments tied to shifts in US immunoglobulin sales channels and softer China albumin prices, ahead of its full-year results and dividend announcement previously scheduled for 18 August 2026.\nDespite these setbacks, investors appear increasingly focused on CSL’s turnaround prospects and the possibility that future impairments could be more contained than previously feared.\nWe’ll now...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","BK4086":"建筑产品","BK7067":"生物科技","BK7508":"医药生物股","CSL.AU":"CSL LIMITED","BK7511":"ESG概念","BK7501":"新冠治疗股","AIPO":"Defiance AI and Power Infrastructure ETF","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC"},"translate_title":"为什么CSL(ASX：CSL)在削减2026财年减值和渠道转移指引后上涨9.8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":0.61,"CSL.AU":1.5,"CSL":1.5},"content_text":"CSL has recently cut its FY26 revenue and profit forecasts following earnings downgrades, writedowns and impairments tied to shifts in US immunoglobulin sales channels and softer China albumin prices, ahead of its full-year results and dividend announcement previously scheduled for 18 August 2026. Despite these setbacks, investors appear increasingly focused on CSL’s turnaround prospects and the possibility that future impairments could be more contained than previously feared. We’ll now examine how renewed investor optimism around a potential operational turnaround, despite recent downgrades and impairments, reshapes CSL’s investment narrative. Find 6 companies with promising cash flow potential yet trading below their fair value.AdvertisementCSL Investment Narrative RecapTo stay invested in CSL today, you need to believe the core plasma and specialty medicines business can absorb channel shifts in US immunoglobulin and softer China albumin pricing, while management stabilises earnings after the FY26 guidance cut. The near term catalyst is the 18 August 2026 full year result and dividend update, where clarity on revenue trends and further impairments will be critical. The biggest risk right now is that write downs and US channel disruption prove larger or longer lasting than expected. Against this backdrop, CSL’s FY26 revenue guidance of about US$15.2 billion, issued on 10 May 2026, is central to the story. It already reflects a reduction versus earlier expectations and sits uncomfortably beside recent impairments and margin pressure. How management updates this outlook at the full year result, particularly in light of weaker China albumin pricing and US immunoglobulin channel changes, will frame how credible any turnaround narrative looks to investors. Yet behind the renewed optimism, investors should be aware of the risk that further impairments and margin pressure from plasma and albumin markets could... Read the full narrative on CSL (it's free!)CSL’s narrative projects $16.9 billion revenue and $3.3 billion earnings by 2029.Uncover how CSL's forecasts yield a A$140.86 fair value, a 31% upside to its current price.Exploring Other PerspectivesASX:CSL 1-Year Stock Price Chart Before the latest downgrade, the most optimistic analysts were pencilling in about US$18.4 billion of revenue and US$4.4 billion of earnings by 2029, which is a far more upbeat story than today’s guidance implies. If you compare that to the current focus on cost cuts and restructuring risk, you can see how far expectations can stretch, and why it is worth exploring several contrasting views on CSL’s future.Explore 12 other fair value estimates on CSL - why the stock might be worth over 2x more than the current price!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your CSL research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.Curious About Other Options?Every day counts. These free picks are already gaining attention. See them before the crowd does:The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AI is about to change healthcare. These 9 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643214189","isCrawlerRequest":true}